



## Supplementary Materials



**Figure S1. Study design and timeline of experiments.** Wild-type C57BL/6J and ErbB4 Cyt-1<sup>fl/fl</sup> adult mice (3-4 month old) were injected uni-/bilateral with AAV (see table) into the VTA. Two weeks after injection mice were subjected to a series of behavioral analyses (open field, elevated plus maze, Y-maze and prepulse inhibition) and histological analyses were performed 4 weeks after injection. Different experiments (Figures 1,2,4,5) tested different AAVs and concentrations summarized in the table. n = number of animals tested.



**Figure S2. Mice with VTA injection of AAV9\_Cre (10<sup>12</sup> GC/mL) exhibit increased activity in the open field.** (A) Scheme visualizing bilateral injection of AAV9\_Cre (1.5 × 10<sup>12</sup> GC/mL) mixed with AAV9\_DIO\_GFP (2.85 × 10<sup>13</sup> GC/mL; mixture final concentration 3 × 10<sup>13</sup> GC/mL and hereafter denoted as Cre) and control AAV9\_GFP (3.0 × 10<sup>13</sup> GC/mL) into the VTA of adult Cyt-1<sup>fl/fl</sup> and WT C57BL/6J mice. (B) Total distance traveled in the open field is significantly different between control and Cre injected mice, independent of genotype (n=5-6/group; two-way ANOVA, F(1, 18)=0.4462, p=0.5126, virus p=0.0210 & genotype = 0.5427). (C) Anxiety assessed in the elevated plus maze is unaffected in Cre- and control-injected mice (n=5-6/group, two-way ANOVA, F(2, 26)=2.046, p=0.1495 & genotype p=0.7452). (D) Working memory measured via novel arm preference in the Y-Maze remained intact across all groups (n=5-6/group, Ordinary one-way ANOVA, F(2, 13)=0.03942, p=0.9615). (E) Sensorimotor gating is largely unaffected (n=5-6/group, two-way ANOVA, F(6, 56)=0.08610, genotype p=0.2586).